Tenon Medical (NASDAQ:TNON) Releases Quarterly Earnings Results, Misses Estimates By $3.95 EPS

Tenon Medical (NASDAQ:TNON) announced its quarterly earnings data on Thursday. The company reported ($12.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($8.40) by ($3.95), FiscalAI reports. The firm had revenue of $1.28 million for the quarter, compared to analysts’ expectations of $1.54 million. Tenon Medical had a negative net margin of 270.09% and a negative return on equity of 907.60%.

Here are the key takeaways from Tenon Medical’s conference call:

• Revenue and gross profit surged: Second-quarter revenue rose 127% year over year to $1.3 million, while gross profit increased 232% to $0.8 million. Gross margin expanded to 64% from 43%, aided by higher procedure volumes and improved fixed-cost absorption.
• Physician and distributor training events increased 98% in the first half versus the second half of 2025, supported by the new Tampa training center. Management said the facility contributed to a record monthly case volume in July and a strong start to the third quarter.
• FDA 510(k) clearance for the updated Catamaran system is expected to reduce per-procedure costs through reusable instruments and improve margins beginning in the third quarter. The company is also preparing enhancements to Symmetry Plus and additional products for potential regulatory filing and launch.
• Tenon raised $4.2 million in gross proceeds through a July 1 public offering, providing additional funding for commercial expansion, clinical research, product development, and partial repayment of convertible notes.
• The company remains loss-making, with a second-quarter net loss of $4.1 million and $1.7 million in cash at quarter-end. Operating expenses increased, and the six-month operating loss was essentially unchanged year over year despite revenue more than doubling; additional non-cash interest expense also increased the net loss.

Tenon Medical Trading Down 7.2%

Shares of NASDAQ:TNON traded down $0.43 on Friday, reaching $5.53. 14,443 shares of the company traded hands, compared to its average volume of 101,258. The business’s 50-day simple moving average is $11.27 and its 200 day simple moving average is $21.43. Tenon Medical has a 52 week low of $4.38 and a 52 week high of $54.95. The stock has a market capitalization of $1.88 million, a P/E ratio of -0.12 and a beta of 1.39.

Institutional Investors Weigh In On Tenon Medical

A number of hedge funds and other institutional investors have recently modified their holdings of TNON. DRW Securities LLC bought a new position in Tenon Medical during the 4th quarter worth approximately $98,000. Geode Capital Management LLC lifted its position in Tenon Medical by 34.6% in the fourth quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock valued at $63,000 after purchasing an additional 17,137 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in Tenon Medical in the first quarter valued at approximately $29,000. Institutional investors own 22.74% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on TNON. Alliance Global Partners reaffirmed a “buy” rating on shares of Tenon Medical in a research note on Wednesday, May 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tenon Medical in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Tenon Medical Company Profile

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.